T1	Participants 54 104	patients with advanced non-small-cell lung cancer:
T2	Participants 284 321	metastatic non-small-cell lung cancer
T3	Participants 1232 1338	QoL questionnaires were completed by 37 pts (88%) in the DCT/CDDP arm and 39 pts (87%) in the VNR/CDDP one
T4	Participants 2829 2875	future trials with chemotherapy plus biologics
T5	Participants 107 197	quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale
